Latest metronidazole Stories
SAN DIEGO, Sept. 21 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has submitted the first section of a rolling New Drug Application (NDA) to the U.S.
SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc.
SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc.
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has submitted a Marketing Authorization Application (MAA) for fidaxomicin to the European Medicines Agency (EMA) under the European Union's Centralized Procedure.
SCHAUMBURG, Ill., May 17 /PRNewswire/ -- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of all lots of metronidazole injection, USP 500mg / 100mL (NDC number 25021-131-82) manufactured by Claris Lifesciences and distributed by Sagent.
SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection (CDI). The data, presented by Stuart Johnson, M.D.
BARRINGTON, Ill., April 14 /PRNewswire/ -- From job interviews to first dates, creating a positive and lasting first impression often goes a long way.
FORT WORTH, Texas, March 22 /PRNewswire/ -- Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration (FDA) approval of DifferinÂ® (adapalene) Lotion, 0.1%, the first-ever lotion formulation of the well-tolerated retinoid adapalene, for the treatment of acne.
SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc.
MALVERN, Penn. and WALTHAM, Mass., Sept. 2 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting.
- Of or relating to good digestion.